Literature DB >> 8335047

European collaborative study of antibiotic prophylaxis for transurethral resection of the prostate.

T B Hargreave1, H Botto, G H Rikken, J R Hindmarsh, T E McDermott, O K Mjolnerod, P Petays, K Schalkhäuser, A Stellos.   

Abstract

A prospective randomised trial was undertaken in nine European Hospitals to test antibiotic prophylaxis for men undergoing transurethral resection of the prostate. Of the men with no significant growth (< 10(4) cfu ml-1) in their preoperative urine, 247 received a single 1 gram dose of ceftazidime with the induction of anaesthesia, 256 received 1 g daily from the time of induction of anaesthesia until removal of the urethral catheter (but < or = 5 days) and 261 received no prophylaxis. Of evaluable patients 83 (33.9%), 45 (18.7%) and 29 (11.6%) of the no-prophylaxis, single-dose and multidose groups, respectively, developed urinary tract infection in the immediate post-operative period. There were significantly fewer febrile episodes and fewer prescriptions for alternative antibiotics in teh ceftazidime-treated groups. For men developed peri-operative septicaemia and all were in the no-prophylaxis group. We conclude that patients, even those with culture-negative urine pre-operatively, benefit from antibiotic prophylaxis and that antibiotic prophylaxis should be considered for all men undergoing prostatic surgery as a routine procedure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335047     DOI: 10.1159/000474649

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

Review 1.  Cost-effective prophylaxis of surgical infections.

Authors:  S R Norrby
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 2.  Fluoroquinolones in urinary tract infections. Proper and improper use.

Authors:  K G Naber
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 3.  Acute urinary retention in men: the risks and outcomes with medical therapy.

Authors:  Timothy B Hargreave; Alan S McNeill
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.